Lisa Licitra
Overview
Explore the profile of Lisa Licitra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
280
Citations
9921
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCoon P, Wang Y, Lai Z, Zhang Q, Li W, Wildsmith S, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40080442
Purpose: Understanding the mutational landscape of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is important in identifying biomarkers to determine which patients may benefit from immune checkpoint inhibitors...
2.
Szturz P, Fuereder T, Guo Y, Licitra L, Mesia R, Ivanyi P, et al.
Cancer Treat Rev
. 2025 Mar;
135:102910.
PMID: 40068239
Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes...
3.
Caspani F, Cavalieri S, Orlandi E, Bergamini C, Resteghini C, Colombo E, et al.
Head Neck
. 2025 Mar;
PMID: 40033633
Background: Lenvatinib, a multi-target tyrosine kinase inhibitor (MTKI), has demonstrated activity in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) in phase II studies. Methods: This multicenter, retrospective study included...
4.
Lenoci D, Serafini M, Lucchetta M, Cavalieri S, Brakenhoff R, Hoebers F, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941896
Background: Despite advances in the management of head and neck squamous cell carcinoma (HNSCC), prognostic models and treatment strategies remain inadequate, particularly for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The...
5.
Gurizzan C, Cinquini M, Legramandi L, Resteghini C, Siano M, Bergamini C, et al.
Ther Adv Med Oncol
. 2025 Jan;
17():17588359241288251.
PMID: 39801611
Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a...
6.
Lenoci D, Resteghini C, Serafini M, Pistore F, Canevari S, Ma B, et al.
Transl Res
. 2024 Dec;
276():21.
PMID: 39689465
No abstract available.
7.
Lenoci D, Moresco E, Cavalieri S, Bergamini C, Torchia E, Botta L, et al.
Front Oncol
. 2024 Oct;
14:1452909.
PMID: 39421447
Oral cavity squamous cell carcinoma (OCSCC) predominantly affects the tongue and the floor of the mouth, primarily in patients over 50 years of age. Incidence and mortality rates vary significantly...
8.
Singer S, Hammerlid E, Tomaszewska I, Amdal C, Herlofson B, Santos M, et al.
Eur J Cancer
. 2024 Oct;
212:115062.
PMID: 39405647
Introduction: Minimal important change estimates (MIC) are useful for interpreting results of clinical research with quality of life (QoL) as an endpoint. For the European Organisation for Research and Treatment...
9.
Cavalieri S, Bergamini C, Lenoci D, Ottini A, Lucchetta M, Torchia E, et al.
Oncology
. 2024 Sep;
103(2):107-111.
PMID: 39231459
Introduction: The objective response rate to immunotherapy is limited in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients, whose prognosis is still dismal. Few prognostic factors are clinically available,...
10.
Ciccone L, Franzetti J, Bonora M, Ronchi S, Camarda A, Charalampopoulou A, et al.
Crit Rev Oncol Hematol
. 2024 Aug;
202:104463.
PMID: 39098367
The role of external beam radiotherapy (EBRT) in thyroid cancer (TC) remains contentious due to limited data. Retrospective studies suggest adjuvant EBRT benefits high-risk differentiated thyroid cancer (DTC) and limited-stage...